Dual-Quantum-Dots-Labeled Lateral Flow Strip Rapidly Quantifies Procalcitonin and C-reactive Protein by XiaoPing Qi et al.
NANO EXPRESS Open Access
Dual-Quantum-Dots-Labeled Lateral Flow
Strip Rapidly Quantifies Procalcitonin and
C-reactive Protein
XiaoPing Qi1, YunYe Huang2, ZhongShi Lin3, Liang Xu3 and Hao Yu2*
Abstract
In the article, a dual-quantum-dots-labeled (dual-QDs-labeled) lateral flow strip (LFS) method was developed for the
simultaneous and rapid quantitative detection of procalcitonin (PCT) and C-reactive protein (CRP) in the blood. Two
QD-antibody conjugates with different fluorescence emission spectra were produced and sprayed on the LFS to
capture PCT and CRP in the blood. Furthermore, a double antibody sandwich method for PCT and, meanwhile, a
competitive inhibition method for CRP were employed in the LFS. For PCT and CRP in serum assayed by the dual-
QDs-labeled LFS, their detection sensitivities reached 0.1 and 1 ng/mL, respectively, and their linear quantitative
detection ranges were from 0.3 to 200 ng/mL and from 50 to 250 μg/mL, respectively. There was little evidence
that the PCT and CRP assays would be interfered with each other. The correlations for testing CRP and PCT in
clinical samples were 99.75 and 97.02 %, respectively, between the dual-QDs-labeled LFS we developed and
commercial methods. The rapid quantification of PCT and CRP on dual-QDs-labeled LFS is of great clinical value
to distinguish inflammation, bacterial infection, or viral infection and to provide guidance for the use of antibiotics or
other medicines.
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Background
C-reactive protein (CRP) is a well-established acute
phase reactive protein that is synthesized by hepatic cells
when there is an invasion by microorganisms in the
human body, or there is tissue damage. Elevated CRP is
a promising indicator of sepsis in neonates and other
age groups. Detection of high concentration of CRP is of
comprehensive clinical significance in the diagnoses of
severity, progress, prognosis, and therapeutic effect of
infection and cancers [26]. CRP concentration in the
serum of normal people is lower than 10 μg/mL. It indi-
cates a risk of infection when the CRP concentration is
higher than 15 μg/mL and severe infection when CRP
concentration reaches 200 μg/mL [24].
Procalcitonin (PCT) is a recently found endogenous,
non-steroidal, and anti-inflammatory material that is
produced when the human body is induced by bacterial
endotoxin when there is a bacterial infection [9]. Under
normal physiological conditions, PCT concentration in
C cells of the thyroid is so low that it can hardly be de-
tected. Bouadma et al. [4] have shown that reference in-
dications of PCT served as a biomarker for the detection
of bacterial infection. In the blood of normal people,
PCT concentration is lower than 0.25 ng/mL. But it is
from 0.25 to 0.5 ng/mL for the people with mild or local
bacterial infection, and from 0.5 to 1 ng/mL for the
people who have a chance of being infected or having
septicemia and thus need dynamic observation, and
from 1 to 100 ng/mL for the people who suffer from
systematic bacterial infection and thus should be closely
monitored as well as given specific anti-infective therapy
and supportive treatment when necessary.
Despite of other potential discriminatory biomarkers
such as IL-6 [7], simultaneous and rapid detection of
CRP and PCT can be helpful in (i) differentiating bacter-
ial infection from non-infective causes of inflammation;
(ii) differentiating acute from chronic bacterial infection as
well as local from systematic bacterial infection; (iii) and
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furthermore, determining the appropriate dosage and dur-
ation of antibiotic therapy [12, 23, 24, 29]. Recently, re-
searches showed that the combination of PCT and CRP
can help assess hematopoietic stem-cell transplant [1]; dis-
tinguish candidemia from bacterial sepsis [11]; also assess
community-acquired pneumonia in children [2].
So far, CRP and PCT concentration can be semi-
quantitatively detected by lateral flow strip (LFS).
Methods for quantitative detection of CRP include
enzyme-linked immunosorbent assay (ELISA) [27], rate
immuno-nephelometry [10], and latex-enhanced immu-
noturbidimetric [15]. Methods for quantitative detection
of PCT include immunofluorescence [17, 21] and immu-
nochemiluminescence [14, 19]. The above-mentioned
methods by which quantitative detection can be con-
ducted are expensive owing to both equipment and de-
tection process, and they are also complicated and time-
consuming. By contrast, detection by LFS is rapid,
simple, and relatively cheap, but the results are semi-
quantitative due to its low detection sensitivity.
Quantum dots (QDs), fluorescent semiconductor
nanoparticles introduced to biomedical research nearly
two decades ago [5, 6], have received attention in recent
years because of a number of attractive features: wide
range of excitation wavelength, narrow and symmetric
spectral peak in its emission spectra, little external inter-
ference, and high stability [13, 18, 20, 28]. Some litera-
tures established the QDs-labeled LFS to rapidly and
quantitatively detect traces of the biomarkers in the
blood or other fluids without pretreatment [3, 8]. To fur-
ther utilize the advantages of QDs, a dual-QDs-labeled
LFS method was introduced in our article for the simul-
taneous quantification of both CRP and PCT in human
blood. In this method, two QD-antibody conjugates with
different fluorescence emission spectra were produced
and strayed on the LFA. A double antibody sandwich
method for PCT, meanwhile a competitive inhibition
method for CRP is adopted in the LFS assay, to minimize
non-specific adsorption and the hook effect. The charac-
teristics of QDs were measured. The characteristics of
dual-QDs-labeled LFS method, such as the sensitivities,
linear quantitative ranges, linearities, interferences, stabil-
ity, and correlations with existing methods, were analyzed
for PCT and CRP assays, respectively.
Methods
Materials
Goat anti-mouse IgG, mouse monoclonal CRP antibody
(CRP135 mAb), mouse monoclonal PCT antibody
(14C12 mAb), its paired mouse monoclonal calcitonin
antibody (14A2 mAb), CRP-free serum, and PCT-free
serum were obtained from Hytest. Analytically pure re-
agents: cadmium oxide (CdO), selenium powder (Se),
powdered sulfur (S), oleic acid (OA), zinc oxide powder
(ZnO), octadecene (ODE), octadecyl amine (ODA),
trioctylphosphine oxide (TOPO), sodium azide were ob-
tained from Sigma-Aldrich; mercaptoacetic acid (MAA),
trichloromethane, normal hexane, methanol, acetone,
heptane, glycine, sodium tetraborate, and sucrose were
from China National Pharmaceutical Group. Standard
human CRP and standard human PCT, bovine serum
albumin (BSA), and phosphate-buffered saline (PBS)
were from Sigma-Aldrich. Guarantee reagents: N-
hydroxysuccinimide (NHS) and carbodiimide (EDC)
were from China National Pharmaceutical Group.
Nitrocellulose membrane and glass cellulose mem-
brane were from Millipore; the whole blood separator
was from Shanghai JieYi Biotechnology; and the
stickiness baseplate was from Shanghai Liangxin Science
and Technology Ltd. Ultrapure water (Milli-Q) is used
in the detections.
Synthesis of QDs
Preparation for hydrophobic CdSe/ZnS QDs is as de-
scribed in reference [22]. Briefly, sulfur precursor is pre-
pared by successively adding 20 mL ODE and 0.06 g S
powdered into the flask and heating them at 150 °C under
nitrogen flow. The zinc precursor is prepared by succes-
sively adding 0.16 g ZnO powder, 5.64 g OA, and 13.7 mL
ODE into the flask and heating them at 310 °C under
nitrogen flow. Four milliliters of ODE, 0.4 mL OA, and
0.3 M CdO are put into a flask and heated to 300 °C. Next,
the solution is cooled to room temperature, and then 2.5 g
ODA and 0.5 g TOPO are added into the flask. After the
solution is heated at 280 °C, 1.8 mL ODE solution with
1.8 M Se is injected into the flask. The CdSe nanocrystals
are grown at 260 °C, and then centrifuged at 12,000 rpm
for 15 min, separated and preserved in hexane.
Three milliliters of ODE and 1 g ODA are loaded into
a flask followed by adding the synthesized CdSe nano-
crystals (preserved in hexane). Heating them in 100 °C
under the nitrogen protection until the hexane is com-
pletely removed. Sulfur (0.52 mL) and zinc precursor are
slowly and successively added, and the temperature is in-
creased to 180 °C and kept for 10 min. And then 0.77 mL
sulfur and zinc precursor are slowly and successively
added, and the temperature is increased to 200 °C and also
kept for 10 min. In accordance to the differences of
growth layers, different volumes of sulfur and zinc precur-
sor are added alternately. The final reaction temperature
is kept at 240 °C, and circulation flux is kept for 1 h. The
obtained CdSe/ZnS QDs is repeatedly purified by adding
10 mL hexane and extracting wastes with methanol, and
then dispersed for use in a small amount of chloroform.
Phase Transfer of QDs
The brief method of synthesizing hydrophobic CdSe/
ZnS QDs into water soluble is as in reference [16] with
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little modification: the hydrophobic CdSe/ZnS QDs is
first precipitated with acetone and then redispersed in
trichloromethane. After that, MAA is added to the solu-
tion. After intensive mixing and standing, the mixture
was stored solution at room temperature for at least 2-h
reaction, until the mixture solution became opaque
which indicates the formation of MAA-QDs. The MAA-
QDs are then centrifuged out at 10,000 rpm for 10 min.
Soft pellet (100–200 μL) is collected and re-suspended
in ultrapure water. The above-mentioned operations are
repeated for two to three times. By the dropwise
addition of 1 mol/L NaOH solution, the pH is adjusted
to 10–11. MAA-QDs are precipitated by adding acetone
and water (50:50 v/v) to the aqueous solution. The pre-
cipitation is slowly dried overnight under mild vacuum
and then slowly re-dispersed under mild agitation in pH
7.2 0.1 mol/L PBS with the final concentration of
1 μmol/L.
Preparation of QD-Antibody Conjugates
Antibodies were attached to the surface of QDs by
chemical crosslinking to obtain QD-antibody conjugates.
The brief procedures are as follows: 60 pmol of QDs,
10 μg of EDC, 15 μg of NHS solution, and 20 μg of
CRP135 mAb solution are added into PBS. And then,
the solution is mixed evenly; the mixed solution is
shaken gently for 24 h at room temperature; after that,
1 mg of glycine for blocking is added in the solution.
The mixture is further separated and purified by
using an ultra-filtration membrane (Microcon YM30,
Millipore) to obtain QD-CRP135 mAb conjugates.
Finally, the purified QD-CRP135 mAb conjugates is
dissolved in PBS and stored at 4 °C for further use.
QD-14C12 mAb conjugates can be obtained by the
same way. The fluorescence emission spectra and
quantum yields of QD-antibody conjugates and hydropho-
bic CdSe/ZnS QDs were acquired with the ultraviolet-
visible (UV-Vis) spectrophotometer (Shimadzu 2450,
Shimadzu) and the fluorescence spectrometer (Ls55,
PerkinElmer).
Preparations for LFS
The LFS consists of several key components, such as a
sample pad, a filter pad, a conjugate pad, a chromato-
graphic membrane, an absorbent pad, and a baseplate.
The QD-CRP135 mAb conjugates and the QD-14C12
mAb conjugates were evenly sprayed onto a pad to make
a conjugate pad by XYZ3000 (Bio-Dot). 14A2 mAb was
sprayed onto the processed chromatographic membrane
to form detection line 1, CRP was fixed to form detec-
tion line 2 and goat anti-mouse IgG was fixed to form
the quality control line. The detection lines and quality
control line are 1.5-mm-wide with 4 mm of space be-
tween two different lines. After the pads were laminated,
the LFS was cut vertically with a slitter into 5-mm wide,
sealed in dry bags and stored at 4 °C.
Design of the Fluorometry System
In this paper, the self-designed fluorometry system was
established, whose elementary structure is shown in
Fig. 1. The system consists of highlight monochromatic
diodes as the excitation light source. The monochro-
matic excitation light irradiates the PCT detection line,
the CRP detection line, and the quality control line on
the LFS. QDs combined on them stimulate different
maximum emission spectra, which are received by CCD
after going through narrow band filters. The CCD is
cooled by a semiconductor freezer and stored at ap-
proximately 10 °C to reduce as much dark current noise
as possible. The emission fluorescence intensity of QDs
combined by PCT and CRP is detected by two different
narrow band filters which are controlled and rotated by
the electric rotating motor. The corresponding CRP and
PCT concentration data are output after a matching
analysis with the computer’s standard curve.
Standard Sample Assay
To produce the standard samples, different amount of
PCT (0–200 ng/mL) were added into the PCT-free
serum solution, as the CRP concentration in the mixture
was fixed at 5 ng/mL, 50 ng/mL, 500 ng/mL, 5 μg/mL,
and 50 μg/mL separately. Similarly, different amounts of
CRP (0–250 μg/mL) were added into the CRP-free
serum, as the PCT concentration in the mixture was
fixed at 5, 50, and 500 ng/mL separately. At room
temperature, 100 μL of standard solution was added
onto the sample pad of the LFS for the reaction. After
15 min of vertical standing, the LFS was inserted into
the self-designed fluorescence detection device, and the
fluorescence intensity from QDs was assayed on detec-
tion lines 1 and 2 and the control line. Every standard
sample was detected five times, and the mean value of
the results was taken.
Clinical Samples Assay
A total of 54 human blood samples from patients with
bacterial infections and from normal people were ob-
tained from Shenzhen Sixth People’s Hospital. Each clin-
ical sample was divided equally into two portions. In one
portion, its CRP concentration was detected by ELISA
and its PCT concentration was detected by immuno-
fluorescence method by hospital. In the other portion,
its CRP and PCT concentrations were detected by dual-
QDs-labeled LFS method established in this paper. Each
sample was detected three times respectively, and the
mean value of the results was taken. Patient consent was
not obtained as all personal identifiers and patient infor-
mation were delinked from the specimens.
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Results
Characterization of the QDs
Fluorescence emission spectra before and after the QDs
are modified are shown in Fig. 2. As it shows, there were
slight redshifts at the fluorescence emission peaks of
QDs after they were modified by antibodies. The max-
imum fluorescence wavelengths emitted were, respect-
ively, 575 and 640 nm with the corresponding peak
width at half height of 40 and 30 nm. The fluorescence
emission peaks were narrow and approximately symmet-
rical. Thirty-four percent quantum yield (QY) was re-
corded for QD-CRP135 mAb conjugates in reference to
Cresyl Violet Acetate (Sigma-Aldrich) in methanol, and
36 % QY recorded for QD-14C12 mAb conjugates, as
compared to 55 % QY recorded for hydrophobic CdSe/
Zn QDs in chloroform.
Principles and Observations of Dual-QDs-Labeled LFS
To overcome the large difference of content ranges be-
tween PCT (ng/mL) and CRP (μg/mL) in the blood to
be assayed, in this paper, the LFS assay developed was
based on double antibody sandwich method for the
detection of PCT and meanwhile competitive inhibition
method for the detection of CRP [25]. By this way, it can
minimize non-specific adsorption and the hook effect
that is likely to occur when the sample concentration is
relatively high.
The specific detection principles are shown in Fig. 3.
When the sample is added onto the sample pad, it
rapidly drenches the conjugate pad and dissolves QD-
14C12 mAb conjugates (QD1-Ab1 for short) and QD-
CRP135 mAb conjugates (QD2-Ab2 for short). If target
PCT exists in the sample, the QD1-Ab1-PCT immuno-
complex is synthesized; meanwhile, if a target CRP
exists, also the QD2-Ab2-CRP is synthesized. Then,
the sample contains QD1-Ab1-PCT, extra QD1-Ab1
unreacted, QD2-Ab2-CRP, extra QD2-Ab2 unreacted,
and other components in the blood. When the sam-
ple flows through detection line 1, QD1-Ab1-PCT is
captured by the fixed 14A2 mAb (Ab3 for short).
QD1-Ab1-PCT-Ab3 is formed and fixed on the detec-
tion line 1 while the remaining sample keeps flowing
without reacting. After that, when the sample keeps
flowing through detection line 2, QD2-Ab2-CRP does
not react with the fixed CRP, while extra QD2-Ab2 is
captured by the fixed CRP and QD2-Ab2-fixed CRP
is formed. The remaining sample including excessive
QD1-Ab1 and uncombined QD2-Ab2-CRP keeps flowing
through the quality control line, and part of it is captured
by goat anti-mouse IgG (Ab4) fixed there. Therefore, there
is a positive correlation between the fluorescent intensity
on detection line 1 and the concentration of PCT, while
there is a negative correlation between the fluorescent
intensity on detection line 2 and the concentration of
CRP. The direct observation of detection effect of the
dual-QDs-labeled LFS is shown in Fig. 4.
Limits of Detection
For PCT, the minimum detection limit is set to be three
times of the standard deviation of the blank control
group’s background signal: SD0 (SD0 = 0.874, n = 5); the
lower limit of quantitative detection is set to be 10 times
of SD0; and the upper limit of quantitative detection is
set to be the calibration curve’s turning point. As shown
in Fig. 5 (left), for PCT, the quantitative detection range
Fig. 1 The schematic structure of fluorescence measuring instrument
Fig. 2 The maximum emission wave of QD-CRP135 mAb conjugates
was 575 nm, and the maximum emission wave of QD-14C12 mAb
conjugates was 640 nm (dashed line: before modification, solid line:
after modification)
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is between 0.3 and 200 ng/mL, and the minimum detec-
tion limit (i.e., sensitivity) is 0.1 ng/mL.
For CRP, since the inhibition method is adopted, the
minimum detection limit of CRP is set to be the control
group’s response T0 minus three times of the standard
deviation SD0 (SD0 = 315.6, n = 5); the lower limit of
quantitative detection to be the control group’s response
T0 minus 10 times of the standard deviation SD0; and
the upper limit of quantitative detection to be the total
amounts of CRP fixed on detection line 2. As shown in
Fig. 5 (right), for CRP, the quantitative detection range is
between 50 ng/mL and 250 μg/mL, and the minimum
detection limit (i.e., sensitivity) is 1 ng/mL.
Calibration Curves, Interference, and Linearity
For PCT, the calibration curves of PCT were estimated
with 11 different concentrations of standard PCT, from
0.2 to 300 ng/mL, diluted in PCT-free serum, when
standard CRP was fixed at five different concentrations
separately. The calibration curves of PCT were plotted
in Fig. 5 (left). The maximum interference rate was
8.5 %, which is set to be the relative percentage between
the maximum deviation and the mean value. The results
indicated few evidences of interference by the concentra-
tions of CRP. The calibration curves were linear fitted,
as a reliable correlation coefficient (R2) was 0.9948, and
a good linearity between fluorescence intensity and PCT
concentration was y = 123.63x + 3.5259.
For CRP, the calibration curves of CRP were estimated
with ten different concentrations of standard CRP, from
1 ng/mL to 250 μg/mL, diluted in CRP-free serum, when
standard PCT was fixed at three different concentrations
separately. The calibration curve of CRP was plotted in
Fig. 5 (right). The maximum interference rate was 5.2 %,
which is set as above. The results also indicated few evi-
dences of interference by the concentrations of PCT.
The calibration curves were also linear fitted, as a reli-
able correlation coefficient (R2) is 0.9838, and a good
Fig. 3 The principle of dual-QDs-labeled LFS testing PCT and CRP simultaneously
Fig. 4 Direct observation of the strip added with 20 ng/mL PCT and 2 μg/mL CRP
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linearity between fluorescence intensity and the logarith-
mic CRP concentration is y = −4485.3Ln(x) + 59,131.
Stability
The stability study of the dual-QDs-labeled LFS was
conducted. The strips airtight preserved at 4 °C and the
normal temperature were assayed at various time points
(weeks 0, 2, 4, 6, 8). The standard solutions were
prepared containing various concentrations of PCT (0.3,
20, 100, 200 ng/mL) and CRP (50 ng/mL, 5 μg/mL,
50 μg/mL, 250 μg/mL). The relative standard deviation
is set to be relative percentage between the standard de-
viation and the mean value. It is found out that the strip
still functions well for detection after 3-month airtight
preservation at normal temperature, as the relative stand-
ard deviations for PCT and CRP were ±6.1 and ±8.4 %,
respectively. Still, functions were well for detection
after 4-month airtight preservation at 4 °C, as the
relative standard deviations for PCT and CRP were ±5.3
and ±4.7 %, respectively.
Contrasting Analysis with Detection Results by Existent
Equipment
The correlations between the detection results by the
hospital and by the dual-QDs-labeled LFS method
established in this paper were shown in Fig. 6. Corre-
lations for CRP and PCT were 99.75 and 97.02 %, re-
spectively, which indicated that the detection results
of PCT by our method and immunofluorescence are
consistent and also indicated the same of CRP by our
method and ELISA. These results mean that the dual-
QDs-labeled LFS method for CRP and PCT has a
good performance compared with other widely com-
mercialized methods.
Fig. 5 (Left) the calibration curve for detecting PCT, when fixed the CRP concentrations. (Right) the calibration curve for detecting CRP (x-axis is in
log coordinates), when fixed the PCT concentrations. (n = 5)
Fig. 6 (Left) comparing testing results of PCT concentrations by our method and immunofluorescence. (Right) comparing testing results of CRP
concentrations by our method and ELISA, shown in double-log coordinates. (n = 3)
Qi et al. Nanoscale Research Letters  (2016) 11:167 Page 6 of 8
Discussion and Conclusions
In this paper, hydrophobic CdSe/ZnS QDs with two dif-
ferent emission spectra were prepared first and modified
by 14C12 mAb and CRP135 mAb, respectively, to pro-
duce QD-antibody conjugates. The QD-antibody conju-
gates were sprayed on the LFS. Furthermore, a double
antibody sandwich method for PCT while a competitive
inhibition method for CRP was employed in the LFS.
Accordingly, the corresponding fluorimetry system is de-
signed for detecting the fluorescence intensity on detec-
tion lines 1 and 2 on the test strip. By testing with
standard samples and clinical samples, the characteris-
tics of QDs and dual-QDs-labeled LFS were analyzed.
There are various advantages of using dual QDs as the
markers in LFS [30]. First, the sensitivity is at least 1 to
2 magnitudes higher than that of colloidal gold, which is
commonly used in LFS. The concentration of PCT in
the blood which can be clinically explained is between 0
and 10 ng/mL. This scope cannot be distinguished by
the existing commercial LFS. While PCT sensitivity de-
tected by the dual-QDs-labeled LFS method established
here reached 0.1 ng/mL, which was consistent with the
sensitivities detected by immunofluorescence method
and immunochemiluminescence. Second, spectra emit-
ted by QDs have a narrow spectral peak. Besides, the
fluorescence spectra can be received by CCD and proc-
essed digitally. In this article, two QD-antibody conju-
gates with different emission spectra were produced and
employed in the LFA to detect PCT and CRP simultan-
eously. There is little interference from the external
lights, and little interference between PCT and CRP
assay. Furthermore, 20 min is enough for testing the
PCT and CRP concentrations in the whole blood by the
dual-QDs-labeled LFS, since blood cells can be filtered
by the whole blood separating membrane and those that
are not filtered move very slowly.
By testing the standard samples and clinical samples, it
was confirmed that the concentrations of PCT and CRP
in the blood can be simultaneously quantified by dual-
QDs-labeled LFS method designed in this paper. For
PCT assaying, the quantitative detection range was from
0.3 to 200 ng/mL and the sensitivity was 0.1 ng/mL,
while for CRP assaying, from 50 ng/mL to 250 μg/mL
and 1 ng/mL, respectively, which are comparable to the
characteristics of the existences. Besides, the step of
serum separation is required in the existing methods.
The dual-QDs-labeled LFS has comparative advan-
tages in that firstly, whole blood can be detected by it
without requirement of serum extraction; secondly,
simultaneous quantification of CRP and PCT can be
conducted within 20 min by using only 100 μL of the
blood; and thirdly, its paired equipment for fluores-
cence detection is simple to operate and also at a low
cost.
However, there are still several problems in the dual-
QDs-labeled LFS designed in this paper. Firstly, the
waste antibodies in producing QD-antibody conjugates
caused the strip at a high cost, due to the low valence of
QDs and the price of monoclonal antibodies. Secondly,
to minimize the hook effect, competitive inhibition
method employed to detect CRP in the dual-QDs-
labeled LFS caused the quantifying limit not low enough
to detect the contents of high-sensitivity CRP (hs-CRP).
Thirdly, the dual-QDs-labeled LFS method needs to be
applied in a temperature-humidity controlled environ-
ment or calibrated frequently, since the fluorescence in-
tensity signal is easily affected by environmental factors.
Nevertheless, dual-QDs-labeled LFS established in this
paper can simultaneously quantify PCT and CRP con-
tents in human blood just in several minutes without
sample pretreatment. It has great value for determining
the severity and prognosis of bacterial infection and pro-
viding guidance for the usage of antibiotics, especially in
the case of emergency or field assay. Furthermore, it also
can help assay some given diseases [1, 2, 11].
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